741-P: Efficacy and Safety of MYL-1601D (Mylan's Insulin Aspart) Compared with Novolog (Novo Nordisk's Insulin Aspart) in Patients with Type 1 Diabetes (T1DM) after 24 Weeks

• Published in: Diabetes (New York, N.Y.) Vol. 70; no. Supplement_1
• Main Authors: RAITER, YARON, BLEVINS, THOMAS, SUN, BIN, DONNELLY, CHARLES M., RAO, ANITA U., SHAPIRO, ROXANN, VASHISHTA, LAXMIKANT, RANGANNA, GOPINATH, CHULLIKANA, ANOOP, BARVE, ABHIJIT
• Format: Journal Article
• Language: English
• Published: New York American Diabetes Association 01.06.2021
• Subjects: Antibody response; Confidence intervals; Diabetes; Diabetes mellitus (insulin dependent); Immunogenicity; Insulin; Patients; Recombinant DNA; Safety
• ISSN: 0012-1797; 1939-327X
• DOI: 10.2337/db21-741-P

MYL-1601D is a rapid-acting human insulin analog produced by recombinant DNA technology utilizing Pichia pastoris yeast. This was a randomized, multicenter, open-label, parallel-group study to compare the safety and efficacy of MYL-1601D with NovoLog in T1DM patients. The primary objective was to demonstrate that treatment emergent antibody response (TEAR) rate with MYL-1601D was equivalent to that of NovoLog by achieving the 90% confidence interval (CI) of treatment difference within the prespecified margin (-12%, +12%) during 24week treatment. The study also compared MYL-1601D to NovoLog, change from baseline to week 24, for the parameters provided in the below Table 1. In total, 478 subjects were included in the intent-to-treat analysis (MYL-1601D: 238, NovoLog: 240) of which, 59 (24.9%) in MYL-1601D and 67 (27.8%) in NovoLog were TEAR responders. The study met its primary objective by showing that the TEAR rate was equivalent between the insulins (the 90% confidence interval difference was within the prespecified margin of -12%, +12%) during 24 weeks of treatment. Efficacy and safety parameters were similar between the two treatment groups. Overall, the study confirmed that MYL-1601D has a similar immunogenicity, efficacy and safety profile to NovoLog.